Riplex

The Problem: The biggest risk to a new drug launch often isn't in the science, but in the supply chain. An undetected quality failure at a contract manufacturing partner (CMO/CDMO) can result in months of delays and millions in losses, jeopardizing a biotech's future. Internal quality systems, by design, have limited visibility into the systemic risks of their external suppliers. Our Solution: Riplex is the external intelligence layer your team is missing. We analyze public and regulatory data (FDA Warning Letters, Form 483s) to identify risk patterns at the industry's top CMOs. We don't just report on events; we connect the dots to provide a strategic perspective on the health and reliability of your supplier network. Our Mission: To give biotech leaders the intelligence they need to protect their most valuable assets, anticipate disruptions, and build a truly anti-fragile supply chain.